BOSULIF vs DANZITEN

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. BOSULIF and DANZITEN are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	BOSULIF	DANZITEN
Rating	New	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	BOSUTINIB MONOHYDRATE	NILOTINIB TARTRATE
Manufacturer	Pf Prism Cv	Azurity
Dosage forms	Capsule, Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Treats	Bcr-Abl Positive Chronic Myelogenous Leukemia	Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors

bosulif danziten

Rating

New

70/100

Pharmacy pays

—

Type

Active ingredient

BOSUTINIB MONOHYDRATE

NILOTINIB TARTRATE

Manufacturer

Pf Prism Cv

Azurity

Dosage forms

Capsule, Tablet

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Treats

Bcr-Abl Positive Chronic Myelogenous Leukemia

Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors

Frequently asked questions

What is the difference between Bosulif and Danziten?

Bosulif contains Bosutinib Monohydrate, while Danziten contains Nilotinib Tartrate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.